Assessment of St Jude Medical Portico Re-sheathable Transapical Aortic Valve System (Portico TA EU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01742598
Recruitment Status : Withdrawn
First Posted : December 5, 2012
Last Update Posted : March 10, 2016
Information provided by (Responsible Party):
St. Jude Medical

Brief Summary:
The purpose of this study is to assess the safety and performance of the 23mm Portico Transcatheter Heart Valve and the TAVI Transapical Delivery System in subjects with severe symptomatic aortic stenosis

Condition or disease Intervention/treatment Phase
Severe Symptomatic Aortic Stenosis Device: Portico Transapical Aortic Valve System Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : December 2015
Estimated Primary Completion Date : July 2016
Estimated Study Completion Date : November 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Portico Implant Device: Portico Transapical Aortic Valve System

Primary Outcome Measures :
  1. All cause mortality [ Time Frame: 30 days ]

Secondary Outcome Measures :
  1. Event rates [ Time Frame: 30 days ]
    • Cardiovascular mortality
    • Myocardial Infarction (MI)
    • Major Stroke
    • Minor Stroke
    • Acute Kidney Injury (AKI)
    • Vascular access site and Access-related complications
    • Bleeding
    • Composite of periprocedural encephalopathy, all stroke, and all TIA

  2. Functional improvements from baseline [ Time Frame: 30 days ]
    • NYHA Functional Classification
    • Six Minute Walk Test
    • Effective Orifice Area (EOA)

  3. Acute device success [ Time Frame: At time of procedure ]
    • Successful apical access, delivery and deployment of the device and successful retrieval of the delivery system,
    • Correct position of the device in the proper anatomical location,
    • Intended performance of the prosthetic heart valve (Aortic Valve Area greater than (>)1.0 cm2 and mean aortic valve gradient less than (<) 20 mmHg or peak velocity less than (<) 3 m/s, without moderate or severe prosthetic valve AR), and
    • Only one valve implanted in the proper anatomical location

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject has signed the study Informed Consent Form and Data Protection Form prior to participating in the study.
  2. Subject is 65 years of age or older at the time of index procedure, and/or has comorbidities that, in the opinion of the Principal Investigator or the Subject Selection Committee, preclude surgical valve replacement.
  3. Subject's aortic annulus is 19-21mm diameter as measured by echocardiography (echo) or CT conducted within 90 days prior to the index procedure.
  4. Subject has senile degenerative aortic stenosis with echocardiography derived mean gradient greater than (>) 40mmHg or jet velocity greater than 4.0 m/s or an initial valve area of less than (<) 0.8 cm2 (or aortic valve area index less than or equal to (≤) 0.6 cm2/m2). (Baseline measurement taken by echo within 90 days of index procedure).
  5. Subject has symptomatic aortic stenosis as demonstrated by NYHA Functional Classification of II, III, or IV.
  6. Subject is deemed high operable risk and suitable for TAVI per the medical opinion of the Subject Selection Committee.
  7. Subject's predicted operative mortality or serious, irreversible morbidity risk is less than (<) 50% at 30 days post index procedure.

Exclusion Criteria:

  1. Subject is unwilling or unable to comply with all study-required follow-up evaluations.
  2. Subject has a documented history of a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within 6 months (less than or equal to (≤) 180 days) prior to the index procedure.
  3. Subject has a chest condition than prevents transapical access.
  4. Subject has carotid artery disease requiring intervention.
  5. Subject has documented evidence of a myocardial infarction (MI) within 6 months (less than or equal to (≤) 180 days) prior to the index procedure.
  6. Subject has a native aortic valve that is congenitally unicuspid, bicuspid, quadricuspid or non-calcified as seen by echocardiography.
  7. Subject has mitral valvular regurgitation greater than (>) grade III.
  8. Subject has moderate or severe mitral stenosis.
  9. Subject has aortic root angulation greater than (>) 70 degrees (horizontal aorta).
  10. The distance from the left ventricular apex to the aortic annulus is less than (<) 45mm (4.5cm).
  11. Subject has a pre-existing prosthetic cardiac device, valve, or prosthetic ring in any position.
  12. Subject refuses any blood product transfusion.
  13. Subject refuses surgical valve replacement.
  14. Subject has left ventricular ejection fraction (LVEF) less than (<) 20%.
  15. Subject has documented, untreated symptomatic coronary artery disease (CAD) requiring revascularization.
  16. Subject has had a percutaneous interventional or other invasive cardiovascular or peripheral vascular procedure less than or equal to (≤) 14 days of index procedure.
  17. Subject has severe basal septal hypertrophy that would interfere with transcatheter valve placement.
  18. Subject has a history of, or is currently diagnosed with endocarditis.
  19. Subject has imaging evidence of intracardiac mass, thrombus, or vegetation.
  20. Subject is considered hemodynamically unstable (requiring inotropic support or mechanical heart assistance).
  21. Subject is in acute pulmonary edema or requiring intravenous diuretic therapy to stabilize heart failure.
  22. Subject with significant pulmonary disease as determined and documented by the Investigator.
  23. Subject has significant chronic steroid use as determined and documented by the Investigator.
  24. Subject has a documented hypersensitivity or contraindication to anticoagulant or antiplatelet medication.
  25. Subject has renal insufficiency as evidenced by a serum creatinine greater than (>) 3.0 mg/dL (265.5µmol/L) or end-stage renal disease requiring chronic dialysis.
  26. Subject has morbid obesity defined as a BMI greater than or equal to (≥) 40.
  27. Subject has ongoing infection or sepsis.
  28. Subject has blood dyscrasias (e.g., leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis, or coagulopathy).
  29. Subject has a current autoimmune disease that, in the opinion of the Principal Investigator or the Subject Selection Committee, precludes the subject from study participation.
  30. Significant ascending aortic disease documented by diameter greater than 40mm.
  31. Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within 90 days prior to the index procedure.
  32. Subject is currently participating in another investigational drug or device study.
  33. Subject requires emergency surgery for any reason.
  34. Subject has a life expectancy less than (<) 12 months.
  35. Subject has other medical, social or psychological conditions that, in the opinion of the Principal Investigator or the Subject Selection Committee, preclude the subject from study participation.
  36. Subject is diagnosed with dementia or admitted to a chronic care facility which would fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits.
  37. Subject has a documented allergy to contrast media, nitinol alloys, porcine tissue, or bovine tissue.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01742598

United Kingdom
King's College Hospital
London, United Kingdom
Sponsors and Collaborators
St. Jude Medical
Principal Investigator: Thomas Walther, MD, PhD Kerckhoff Klinik

Responsible Party: St. Jude Medical Identifier: NCT01742598     History of Changes
Other Study ID Numbers: 1106
First Posted: December 5, 2012    Key Record Dates
Last Update Posted: March 10, 2016
Last Verified: December 2015

Keywords provided by St. Jude Medical:
aortic stenosis
valvular heart disease
aortic valve stenosis
aortic valve replacement
transcatheter aortic valve implantation

Additional relevant MeSH terms:
Constriction, Pathologic
Aortic Valve Stenosis
Pathological Conditions, Anatomical
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction